


CANCER

Principles & Practice of Oncology



5th Edition

*Vincent T. DeVita, Jr.
Samuel Hellman
Steven A. Rosenberg*


Compliments of

DOCKET
A L A R M

Find authenticated court documents without watermarks at docketalarm.com.

CANCER

Principles & Practice of Oncology



5th Edition



Lippincott - Raven

P U B L I S H E R S

Philadelphia • New York

Project Editor: Grace R. Caputo
Production Manager: Caren Erlichman
Senior Production Coordinator: Kevin P. Johnson
Design Coordinator: Melissa Olson
Indexers: Linda K. Fetters and Alexandra Nickerson
Compositor: Maryland Composition Company
Printer: Rand McNally, Taunton, MA.

5th Edition

Copyright © 1997 by Lippincott–Raven Publishers.

Copyright © 1993, 1989, 1985, 1982 by J.B. Lippincott Company. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means—electronic, mechanical, photocopy, recording, or otherwise—without the prior written permission of the publisher, except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write Lippincott–Raven Publishers, 227 East Washington Square, Philadelphia, PA 19106-3780.

Materials appearing in this book prepared by individuals as part of their official duties as U.S. Government employees are not covered by the above-mentioned copyright.

Library of Congress Cataloging-in-Publication Data

Cancer: principles and practice of oncology/[edited by] Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg; 290 contributors.—5th ed.

p. cm.

Includes bibliographical references.

Includes index.

ISBN 0-397-51573-1 (one-vol. ed.)

ISBN 0-397-51574-X (two-vol. set)

ISBN 0-397-51575-8 (vol. 1)

ISBN 0-397-51576-6 (vol. 2)

ISSN 0892-0567

1. Cancer. 2. Oncology. I. DeVita, Vincent T., Jr. II. Hellman, Samuel. III. Rosenberg, Steven A.

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editors, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, express or implied, with respect to the contents of the publication.

The authors, editors, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice.

9 8 7 6 5 4 3 2 1

Pathology and Biologic Features	2243
Diagnosis and Staging	2249
Patterns of Clinical Presentation	2252
Immunologic Abnormalities	2254
Treatment	2255
Hodgkin's Disease in HIV-Positive Patients	2274
Complications of Therapy	2274
New Drugs and Biologics in Hodgkin's Disease	2274

45**Leukemias** 2285**SECTION 1** *Molecular Biology of the Leukemias* 2285

ISSA KHOURI

FELIX GARCIA SANCHEZ

ALBERT B. DEISSEROTH

Chronic Myelogenous Leukemia 2285**Acute Myelogenous Leukemia** 2287**Changes in CML** 2289**Genetic Changes in ALL: Enumerative Chromosomal Abnormalities of Leukemic Syndromes** 2289**Chimeric Transcriptional Regulatory Proteins in ALL** 2290**Translocations Resulting in Lineage-Specific Patterns of Transcriptional Regulatory Proteins** 2290**Leukemic Syndromes Organized by the Chromosomes Involved** 2291**Application of the Structural Information Derived From the Study of Chromosomal Translocations to the Therapy of Leukemia and Solid Tumors** 2292**Summary** 2292**SECTION 2** *Acute Leukemias* 2293

DAVID A. SCHEINBERG

PETER MASLAK

MARK WEISS

Epidemiology and Etiology 2293**Biology of Acute Leukemias** 2295**Diagnosis and Classification of Acute Leukemias** 2296**Principles of Therapy for Acute Leukemia** 2300**Principles of Clinical Management of Acute Leukemia** 2303**Treatment of Newly Diagnosed Acute Myelogenous Leukemia** 2304**Treatment of Relapsed Acute Myelogenous Leukemia** 2308**Acute Promyelocytic Leukemia** 2310**General Principles for the Treatment of Adult Acute Lymphoblastic Leukemia** 2310**Prognostic Features in Adult Acute Lymphoblastic Leukemia** 2311**Treatment of Newly Diagnosed Adult Patients With Adult Lymphoblastic Leukemia** 2312**Treatment of Relapsed or Refractory Adult Patients With Acute Lymphoblastic Leukemia** 2313**Central Nervous System Relapse in Adult Acute Lymphoblastic Leukemia** 2314**Bone Marrow Transplant for Adult Acute Lymphoblastic Leukemia** 2314

Treatment of Mature B-Cell Acute Lymphoblastic Leukemia 2314
Granulocyte Sarcomas, Leukemia Cutis, and Other Extramedullary
Leukemic Involvement 2315
Biological and Immunological Therapies of Acute Leukemias 2315
Conclusion 2316

SECTION 3 *Chronic Leukemias* 2321

ALBERT B. DEISSEROTH
HAGOP KANTARJIAN
MICHAEL ANDREEFF
MOSHE TALPAZ
MICHAEL J. KEATING
ISSA KHOURI
RICHARD B. CHAMPLIN

Chronic Lymphocytic Leukemia 2321
Prolymphocytic Leukemia 2327
Hairy Cell Leukemia 2327
T-Cell Chronic Lymphocytic Leukemia 2328
Chronic Myelogenous Leukemia 2328
Summary 2338

SECTION 4 *Plasma Cell Neoplasms* 2344

SYDNEY E. SALMON
J. ROBERT CASSADY

History 2344
Incidence and Mortality 2346
Pathogenesis 2347
Pathology 2349
Diagnosis and Clinical Staging of Myeloma 2352
Treatment 2355
Complications and Special Problems 2369
Other Plasma Cell Neoplasms 2375
Perspective 2379

SECTION 5 *Myelodysplastic Syndromes* 2388

DAVID A. SCHEINBERG
PETER MASLAK
MARK WEISS

Incidence, Etiology, and Classification 2388
Biology of Myelodysplastic Syndromes 2389
Diagnosis 2389
Prognosis in Myelodysplastic Syndromes 2390
Specific Syndromes of Myelodysplastic Syndromes 2391
Chronic Myelomonocytic Leukemia 2391
Treatment of Myelodysplastic Syndromes 2391
Hematopoietic Growth Factors 2392
Drug Therapy of Myelodysplastic Syndromes Including
Chemotherapy 2393
Allogeneic Bone Marrow Transplantation for Myelodysplastic
Syndromes 2394

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.